Format

Send to

Choose Destination
Radiother Oncol. 2015 Jun;115(3):314-20. doi: 10.1016/j.radonc.2015.05.021. Epub 2015 Jun 16.

Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study.

Author information

1
Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway. Electronic address: Marte.Cameron@sshf.no.
2
Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway.
3
Department of Obstetrics and Gynecology, Sørlandet Hospital, Kristiansand, Norway.
4
Department of Oncology, Innlandet Hospital, Gjøvik, Norway.
5
Department of Oncology, Oslo University Hospital, Norway.
6
Department of Oncology, Stavanger University Hospital, Norway.
7
School of Pharmacy, University of Oslo and the Norwegian Institute of Public Health, Norway.
8
Department of Oncology, Oslo University Hospital, Norway; K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Norway.

Abstract

BACKGROUND AND PURPOSE:

Radiotherapy is used to palliate pelvic symptoms of castration resistant prostate cancer (CRPC). However, magnitude and time course of effects and toxicities are poorly documented. Study aims were to evaluate changes in patient-reported target symptoms (TS), health-related quality of life (HRQOL) and toxicity following palliative pelvic radiotherapy (PPRT) of CRPC.

MATERIAL AND METHODS:

47 patients with CRPC and a symptomatic pelvic mass prescribed PPRT with 30-39 Gy were prospectively included. Primary endpoint was patient-reported improvement or complete resolution of the TS twelve weeks after PPRT. HRQOL changes were explored. Toxicity was physician-evaluated.

RESULTS:

Lower urinary tract symptoms (LUTS) (45%), hematuria (26%) and pain (19%) were the most common TS. In the 40 evaluable patients, overall TS response twelve weeks after PPRT was 70%. TS responses were 8/18 for LUTS, 11/12 for hematuria, and 7/9 for pain. Global HRQOL improved transiently. The most common toxicity was grade 1 or 2 diarrhea (50%). There was no grade 4 toxicity.

CONCLUSIONS:

In the majority of patients with CRPC and a symptomatic pelvic tumor, PPRT with 30-39 Gy contributes to relief of hematuria, pain and other pelvic symptoms, with acceptable toxicity. Future studies should investigate whether PPRT regimens can be simplified.

KEYWORDS:

Palliative radiotherapy; Pelvic tumor; Prostate cancer; Quality of life; Symptoms; Toxicity

PMID:
26091575
DOI:
10.1016/j.radonc.2015.05.021
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center